Asthma/COPD spray - EmphycorpAlternative Names: EMPHYCLEAR™ COPD nasal spray
Latest Information Update: 10 Mar 2016
At a glance
- Originator Emphycorp
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Interstitial lung diseases